Welcome to our dedicated page for Eton Pharmaceuticals news (Ticker: ETON), a resource for investors and traders seeking the latest updates and insights on Eton Pharmaceuticals stock.
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is a pharmaceutical company focused on developing and commercializing treatments for rare diseases, with particular emphasis on pediatric endocrinology and other rare endocrine and metabolic disorders. Its 2025 press releases highlight a growing portfolio of eight commercial rare disease products, including KHINDIVI, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone, along with late-stage candidates such as ET-600, Amglidia, ET-700, ET-800, and the ZENEO hydrocortisone autoinjector.
The ETON news feed features updates on FDA regulatory milestones, product launches, financial results, and corporate developments. Examples include the U.S. FDA approval of KHINDIVI (hydrocortisone) Oral Solution for pediatric adrenocortical insufficiency, the FDA’s acceptance of the New Drug Application for ET-600 (desmopressin oral solution) with a specified PDUFA target action date, and quarterly earnings reports detailing product sales growth and pipeline investment. The company also reports on its acquisition and relaunch of INCRELEX and GALZIN, and on its inclusion in the Russell 2000 and Russell 3000 indexes.
Investors following ETON news can track how Eton’s commercial portfolio and pipeline evolve through regulatory decisions, label expansion efforts, clinical study plans, and conference participation. Regular press releases also discuss non-GAAP metrics such as Adjusted EBITDA, providing additional context for financial performance. This news page aggregates these company-issued updates so readers can review Eton’s rare disease strategy, key product milestones, and ongoing engagement with the healthcare and investment communities.
Eton Pharmaceuticals, Inc reported robust financial results for Q1 2024, with revenue of $8.0 million, a 50% increase over Q1 2023. The company achieved its 13th consecutive quarter of sequential product sales growth, acquired PKU GOLIKE®, launched Nitisinone, and submitted an NDA for product candidate ET-400. Eton anticipates strong growth in 2024, driven by existing products and new additions, positioning itself for a potential successful launch of ET-400 in early 2025.
Eton Pharmaceuticals, Inc (Nasdaq: ETON) will present at the Citizens JMP Life Sciences Conference in New York on May 13, 2024. Sean Brynjelsen, CEO, and James Gruber, CFO, will participate. For meeting requests, contact Citizens JMP.
Eton Pharmaceuticals submitted a New Drug Application (NDA) for ET-400, a hydrocortisone oral solution with patent protection through 2043. The company expects potential approval by Q1 2025, aiming for combined peak sales of over $50 million annually.
Eton Pharmaceuticals, Inc. will report its first quarter 2024 financial results on May 9, 2024. The company focuses on developing treatments for rare diseases. A conference call and webcast will discuss the results at 4:30 p.m. ET on the same day. Investors can email questions or access the webcast on Eton's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.